Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's not over and this script for an episode of CNBC's "American Greed" is still writing itself.
I make comments primarily on the 10-K and financials, you must have me confused with the other posters with your comment: "that was the supposedly the only issue "
I have said there are many, many issues with $CYDY since a friend had me watch back at $2.79 on down.
You are correct, "never a dull moment with this stock" and "real longs" are learning a stock market lesson the hard way.
The toxic lenders now run the show and will install another board member to protect whatever value is salvageable. But, we read the 10-K and the equity has no financial value, in fact $CYDY shareholder equity is negative so what's the value?
The value is the story and well... we know how that's going ...not even paid pumps can spin this dog.
It's OUTSTANDING news Nader is gone, but that's not the top issue for $CYDY.
It's OUTSTANDING for leronlimab if it can be further developed without a criminal running the show.
Why? because by continually repartitioning the notes keeps up better appearances.
There are some tax and accounting reasons for the lender too, but I'm not a special operative toxic lending bookrunner to know exactly how that part works.
"Fife and crew reloaded with shares to sell"
There is plenty of ammo left to fire off at "REAL LONGS"
Only a complete corporate restructure can "save" leronlimab from $CYDY
A standard OTC wash, rinse, repeat is due using bankruptcy along with a name and symbol change.
The SEC needs to shut this shit show down.
"CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab"...
$CYDY is NOWHERE near "commercialization", the SEC is going to shut this company down.
These modifications to increase the toxicity of the financing will continue upon every price drop until the PPS is sub-penny.
The true disposition of the FDA post Aduhelm is yet to be known. The situation has created MORE uncertainty as politics, policy, science and money collide.
Exiting $TRTC, as I constantly recommended, was definitely the correct move.
That said, this ticker is now completely different company in terms of improving the basic financials and corporate structure. So I'm long just for fun on that front.
But... California is a very difficult place to operate (legally) and I won't pass judgement until I see the next financial statement to evaluate business performance.
LOL, classic cult stock visual
Not sure? Little ol' $UNRV isn't something I really follow closely.
"Go bankruptcy! Go DOJ and SEC" Free leronlimab!
I've read online it's a miracle drug.
The average warrant conversion price doesn't provide the full picture.
Based on the faux bounce to the low $0.70, I suspect there are many warrants exercisable below $0.70, as we know from the financial filings the lowest warrant exercise price is $0.30.
Correct but if you overlay and account for a "beta" type calculation $AVXL and the biotech indexes are correlated.
This is a side effect of large institutional index ownership.
Not a who, a what is "hurt", for example $CYDY's share price.
To be clear I never said anything about "withholding" anything, which by the way is $AVXL's prerogative anyway.
Sector rotation out of biotech continues per the relevant indexes, that's money in motion.
Is the new mantra?
Be investors.
Truth hurts... can't spin the 10-Q
Maybe the DOJ showed up with the warrants...
I'm still confused by all the cryassing from long term holders.
Unless they are part of the cabal too?!?
IMO, $AVXL's stock price will go however the indexes go without an outside force like Rett results.
Looks like Dr. Missling didn't want to mix science with investing presentations as is usual, but I know many eyes are watching and that's a good time to release the data.
If "investors" learned the basics of how to read a 10-K versus reading echo chamber hype they would be much wealthier.
I haven't been following $CYDY for very long, and have never had a position long or short, but I do like to watch a good stock story unfold.
Unfortunately this is a sad story.
Shorts smell blood. As regarding $CYDY, the chart, financials, and lack of robust trial data is in shorts favor.
I agree many lies out there. That's why my DD and posts are primary sourced from SEC documents.
No duh... I never said they were if your comment was to me.
Simply commenting on how tomorrow could roll and be regulation FD compliant.
Minor correction, $CYDY filed a S-3 secondary shelf offering on March 3, 2021 that has not been declared effective and probably never will be.
Link to S-3: https://www.sec.gov/Archives/edgar/data/0001175680/000119312521067849/d435677ds3.htm
"Release PR, do the JPM then do the HC or vice versa." Is fully compliant with regulation FD and would make for an exciting day.
No new information was provided at the HC Wainwright conference, but not following through with their own timeline is frustrating even if nothing new was presented.
Incorrect in the $CYDY situation, as the flow of equity is restrained without an effective shelf S-3. Therefore $CYDY is restricted to regulation D deals and the burdens of rule 144 that come with it.
"REALITY IS SAD", true, but it's all good and caveat emptor when using proper disclosure and forward looking language.
How did you derive $0.50?
I've been using the warrant exercise prices as the support levels the MM's would try to hold for their share selling buddies.
I expected a death spiral if $1 fell, but nothing that pegged $0.50 specifically.
Great guess of a round psychological number if a guess.
The financials show $CYDY is in a dire situation and common equity is worthless.
The $2.50 per share cash requirement wasn't even a true "cost to carry" in this low interest rate environment.
Bravo...Bravo!
I'm absolutely positive retail warrant holders have had a very difficult time exercising and selling $CYDY under rule 144.
Most brokerage firms probably won't even accept in the certificates or a transfer in. Plus many brokers now charge commission for OTC trades starting 2022.
Retail investing tip..avoid OTC and especially with warrants.
I thought the last financials were bad. The common equity is worthless.
Inside joke in the phrase "HOLD LONG!!!" for Anavex investors.
At least that's how I took it.
HOLD LONG, DON'T LET SHORTY STEAL YOUR SHARES... LOL!!!!
Good luck financing this disaster as $CYDY can only do regulation D offerings of unregistered shares.
Ain't nobody got time for 6 months of rule 144 risk on that crap!
But with 12% placement bonus, at $0.40 plus generous warrants, maybe a firm will do the deal.
"there has never been any validated good news," or productive news either.
"The last proactive video, NP said he would go Fund Raise."
I'm sure he will try as there are firms lower thanFife and Paulson that will do small toxic deals. However, I bet warrants won't be an option anymore. The toxic terms of equity financing will be at a direct discount to the market price.